New Diabetes Research Study Starts at New York Hospital Queens Family Members of Those With Type 1 Diabetes Invited to Participate
Posted on: Tuesday, 24 October 2006, 15:00 CDT
NEW YORK, Oct. 24 /PRNewswire/ -- Type 1 diabetes is a life-long disease that can affect both children and adults. New York Hospital Queens is offering area residents a chance to participate in a new diabetes study to help researchers learn more about what causes type 1 diabetes.
Our hospital is participating with Trialnet, a network of 18 international clinical sites, to enroll participants in the first phase of the study -- the Natural History Study of the Development of Type 1 Diabetes. New York Hospital Queens is the only institution in Queens partnering with this growing network, and the relationship represents a widening of the hospital's support of diabetes research and treatment.
The goal of this study is to learn more about how type 1 diabetes develops in "at risk" individuals. This study also provides close monitoring to individuals at risk for developing the disease.
To be eligible for this study: * Participants must be 1 to 45 years of age and have a brother, sister, child or parent with type 1 diabetes. * Participants must be 1 to 20 years of age and have a cousin, aunt, uncle, niece, nephew, half-sibling or grandparent with type 1 diabetes.
For more information or to determine eligibility, potential participants can call (718) 670-2414.
Diabetes Prevalence & Research -- Right Here in Queens
The American Diabetes Association estimates that 20.8 million U.S. residents have diabetes, and of these, 5 to 10 percent have type 1 diabetes (also known as insulin-dependant or juvenile diabetes). According to the New York City Department of Health and Mental Hygiene, there are 8,000 people with type 1 diabetes who live in Queens.
Type 1 diabetes causes the body to attack and destroy cells in the body that make insulin -- a hormone required by the body to process food into energy. Diabetes is closely linked to complications such as heart disease, high blood pressure, blindness, kidney disease, nerve disease and the risk of limb amputation. If left untreated, diabetes can cause death.
"Research at our Lang Center focuses on finding improvements for the treatment of diseases that physicians can use in everyday practice. Since diabetes is such a serious disease, and a growing issue here in Queens, we devote a significant amount of effort to the study of it," said Daniel Lorber, M.D., FACP, CDE, Director of Metabolic and Diabetes Research at the Lang Center for Research and Education at New York Hospital Queens. Dr. Lorber explained that the ability to identify people at risk is crucial to managing this disease. "Now, our participation in TrialNet provides the opportunity to find and help these individuals," he said.
Trialnet sites, such as New York Hospital Queens, have researchers who are experts in both diabetes and the body's immune system. They share common scientific goals related to the study, treatment and prevention of type 1 diabetes.
New York Hospital Queens is a long-time supporter of the Juvenile Diabetes Research Foundation. The hospital currently has 100 ongoing clinical trials in various disease categories and focuses on research that can affect medical practice and patient care.
TrialNet Background
TrialNet centers collaborate in the investigation of therapies to address type 1 diabetes. The goal of TrialNet is to perform intervention studies to preserve insulin-producing cells in individuals at risk for type 1 diabetes and in those with new onset type 1 diabetes. Studies are designed to help understand the natural history and provide insight into the mechanisms of the disease. TrialNet focuses on identifying individuals "at risk" for developing type 1 diabetes. Risk is based on having autoantibodies (antibodies that react with a person's own cells) or other markers and results of certain tests relating to glucose tolerance.
TrialNet screening and enrollment sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet is supported by the United States National Institutes of Health and Department of Health & Human Services, Juvenile Diabetes Research Foundation International, and the American Diabetes Association.
New York Hospital Queens is a member of the NewYork-Presbyterian Healthcare System and is an affiliate of the Weill Medical College of Cornell University. For more information on New York Hospital Queens go to http://www.nyhq.org/.
Contact: Cynthia Bacon (718) 670-2515
New York Hospital Queens
CONTACT: Cynthia Bacon, +1-718-670-2515
Web site: http://www.nyhq.org/
Source: PRNewswire
Related Articles
- Kidney Disease Increases the Risk of Stroke in Patients With the Most Common Type of Heart Arrhythmia, According to Kaiser Permanente Study
- Viral Genetics Reports Initial Findings From Lyme Disease Study
- Viral Genetics, Inc. Releases Initial Findings of Lyme Disease Study
- Hadasit Reports Positive Results of Phase I Immune Diseases Study
- Elmhurst and Queens Hospital Centers &Amp; Axolotl Partner to Improve Patient Care in New York
- Abdominal Fat Distribution Predicts Heart Disease: Study
- HIP Health Plan Launches New York City's First Health Plan to Address Diabetes Epidemic Among New York's Medicare Population
- Diabetes on the Rise Among America's Youth, Study Shows
- Viscogliosi Brothers Receive First Ever Industry Leadership Award From NYU Hospital for Joint Diseases
- Green Tea Ingredient Protects Brain Against Alzheimer's Disease: Study
 |
 |
User Comments (0)
RSS Feeds